Beatriz Liliana Areces

Title: Beatriz Liliana Areces: Innovator in Medical Diagnostics

Introduction

Beatriz Liliana Areces is a prominent inventor based in Milan, Italy. She has made significant contributions to the field of medical diagnostics, particularly in the development of antibody tools for therapeutic applications. Her innovative work focuses on improving treatment methodologies for disorders treated with histone deacetylase (HDAC) inhibitors.

Latest Patents

Beatriz holds 1 patent for her invention titled "Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases." This invention relates to a method for determining whether a treatment of a disorder with an HDAC inhibitor should be initiated or continued. The method involves assessing the level of histone acetylation in a sample using an antibody that binds to acetylated histone. If the level of histone acetylation is significantly lower than that of a reference sample, the disorder is classified as one that should be treated with an HDAC inhibitor. Additionally, her invention encompasses the diagnostic and prognostic use of specific antibodies and cell lines that produce them.

Career Highlights

Beatriz is currently associated with Topotarget Germany AG, where she continues to advance her research and development efforts. Her work has been instrumental in bridging the gap between basic research and clinical applications, enhancing the understanding of HDAC inhibitors in medical therapy.

Collaborations

Throughout her career, Beatriz has collaborated with notable professionals in her field, including Giuseppe Pier Pelicci and Saverio Minucci. These collaborations have enriched her research and contributed to the advancement of medical diagnostics.

Conclusion

Beatriz Liliana Areces is a trailblazer in the field of medical diagnostics, with her innovative patent addressing critical needs in the treatment of disorders with HDAC inhibitors. Her contributions continue to impact the medical community positively.